Alumis’ (ALMS) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Alumis (NASDAQ:ALMS)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a report released on Thursday,Benzinga reports.

Other research analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $15.00 price objective (down from $19.00) on shares of Alumis in a research report on Thursday. Oppenheimer started coverage on Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price target for the company. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $26.00.

Alumis Stock Performance

NASDAQ ALMS traded down $0.04 on Thursday, reaching $4.33. 4,156 shares of the company were exchanged, compared to its average volume of 170,166. The business’s fifty day moving average price is $5.84 and its 200 day moving average price is $8.69. Alumis has a fifty-two week low of $4.24 and a fifty-two week high of $13.53.

Institutional Trading of Alumis

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Tang Capital Management LLC raised its holdings in shares of Alumis by 40.6% in the fourth quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock valued at $4,716,000 after purchasing an additional 173,406 shares during the last quarter. Foresite Capital Management V LLC increased its position in Alumis by 3.5% during the 4th quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after purchasing an additional 194,459 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Alumis by 1,257.0% during the fourth quarter. BNP Paribas Financial Markets now owns 34,835 shares of the company’s stock worth $274,000 after buying an additional 32,268 shares during the last quarter. Ally Bridge Group NY LLC increased its holdings in Alumis by 6.4% in the 4th quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company’s stock worth $3,500,000 after purchasing an additional 26,843 shares in the last quarter. Finally, Foresite Capital Management VI LLC acquired a new position in Alumis during the 4th quarter worth about $33,033,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.